In light of their promising biological activities and intriguing architectural features, 13-MePB and 13-MeTHPB alkaloids have been privileged targets of synthetic and medicinal chemists for decades. However, the C13 substitution coupled with the C13/C14
cis stereochemical characteristic give rise to more synthetic challenges. The semisynthetic sequence involving acetonation, alkylation with MeI and non-selective reduction was among the traditional transformations towards 13-MePB and 13-MeTHPB alkaloids (
Scheme 1a) [
16]. Cushman, Taylor and Seidel separately developed Mannich-type cyclization strategies to construct 13-MeTHPB alkaloids [
17-
19], but these syntheses either delivered racemic products or needed the help of resolution approach. Recently, some synthetic methodologies based on transition metal catalyzed cyclization were reported in 13-MePB scaffolds assembly, such as Cheng's Rh-catalyzed C-H bond activation [
20] and Donohoe's Pa-catalyzed enolate arylation [
21]. While Tong and coworkers documented an enantioselective synthesis of 13-MeTHPB alkaloids featuring a new Cu-catalyzed asymmetric redox-A
3 reaction followed by Pd-catalyzed cyclization, they also investigated the one step oxidation of racemic 13-MeTHPB to 13-MePB (
Scheme 1b) [
22,
23]. Moreover, Cozzi and colleagues developed an organocatalytic reaction to synthesize 13-MeTHPB with 3.5:1
dr in the formation of the crucial C13/C14 relative stereochemistry (
Scheme 1c) [
24]. Most recently, Hailes and coworkers achieved syntheses of enantioenriched 13-MeTHPBs with opposite absolute configurations to natural members by utilizing their developed chemoenzymatic cascade approach, and further forged corresponding 13-MePBs through single step, albeit with comparatively low isolated yields (
Scheme 1d) [
25]. Despite these impressive advances, many methods usually required precisely prepared substrates, and/or precious metals, harsh reaction conditions, and lengthy chemical processes, complicating reaction work up and making scale-up challenging and cumbersome. Therefore, it is highly desirable to develop an alternative route that utilizes low-cost chemical inputs to structurally diverse 13-MePB and 13-MeTHPB alkaloids with highly atom-economical manner. Motivated by these requirements, we embarked on a research program aimed at the exploration of a practical approach that can access both 13-MePB and 13-MeTHPB alkaloids in a streamlined synthesis manner. Strategically inspired by synthetic studies on berberine by the research groups of Clift and Jiang [
26,
27], we conceived that a one-pot Pictet-Spengler/Friedel-Crafts hydroxyalkylation/dehydration/oxidation sequence of secondary amine hydrochloride
5 and methylglyoxal
6 could be a straightforward and completely atom-economical approach for constructing 13-MePB alkaloids (
Scheme 1e). It is well known that asymmetric catalytic hydrogenations of imines and enamines are among the most green and powerful approaches for the elaboration of chiral amine moieties in natural products [
28]. Therefore, if the subsequent asymmetric hydrogenation of 13-MePB scaffolds could be manipulated with high-level enantiocontrol, it would be possible for us to access the corresponding 13-MeTHPB alkaloids. In fact, we are aware that this transformation could be challenging since Tong disclosed only one example of Noyori transfer hydrogenation of 13-MePB with 20%
ee and speculated that the C13 substitution generated a significant influence on the enantioselectivity of the hydrogenation. Our group previously described an Ir-catalyzed hydrogenation approach of dihydroprotoberberine cores to enantioenriched THPB alkaloids [
29]. We envisaged that this approach could be fascinating alternative and expect to employ the Ir-catalyzed asymmetric hydrogenation of 13-MePBs for establishing the more challenging C13/C14
cis stereochemistry of 13-MeTHPBs. In the following sections, we describe our synthetic strategy and de novo syntheses of the aforementioned alkaloids in detail.